fertility are well known: fertility is reduced in up to 70% of patients with HD (Viviani et al., 1991), but the cause thereof Lymphomas are a group of diseases, prevalent at reproductis not completely understood. Fever, general state of a patient ive age. Fertility is notoriously reduced among lymphoma suffering from a malignant disease and psychological factors patients. This study evaluates pre-and post-treatment were all suggested as possible causes. Infertility is also possibly semen concentration and motility, and factors associated immune-mediated (Barr et al., 1993). Chemotherapy and with semen quality deterioration. We followed-up 33 irradiation further contribute to infertility. Testicular damage patients with non-Hodgkin's lymphoma or with Hodgkin's may be irreversible, but even if reversed, repair may take as disease during the years 1987-1997 who were referred for long as 20 years (Marmor and Duyck, 1995). New treatment semen cryopreservation. Pretreatment semen analysis, and regimens have increased patient survival substantially, so that hormonal profile were recorded at diagnosis and at least more patients at the reproductive age are living and are 1 year after completion of the treatment, and compared.
Introduction ment protocols, and minimizes the risk of infertility among lymphoma patients. Lymphomas are defined as a group of malignant diseases characterized by infiltration of lymph nodes with malignant cells that destroy their architecture. Hodgkin's disease (HD) is identified histologically by large, binucleated Reed-Sternberg Materials and methods cells in lymph node biopsies. Non-Hodgkin's lymphomas The study population comprised 33 patients, derived from 112 (NHL) are a large group of diseases, defined as any lymphoma consecutive lymphoma patients referred to our centre for semen cryopreservation prior to initiation of treatment between the years that is not HD. HD and NHL are biologically and clinically 12-93 months). We tried to find a relationship between follow-up Post-treatment (%) 17 (51.5) 1 (3.0) 15 (45.5) period and sperm quality as reflected by sperm concentration. Blood samples for testosterone and FSH concentrations were taken before commencing treatment and at the end of the follow-up period. Semen samples (range: 1-20, mean: 5.4 samples per patient) were collected vinblastine and dacarbazine (ABVD) and mechloretamine, vincristine, procarbazine and prednisone with ABV (MOPP-ABV). Among the sperm concentration and on the existence of motile spermatozoa. 29 patients treated with chemotherapy, 10 received ABVD, nine
One-way analysis of variance (ANOVA) was used to evaluate the received MOPP-ABV and 10 were treated with other protocols.
effect of hormonal profile on change in sperm concentration and on Patients were classified into three categories according to sperm the existence of motile spermatozoa; P Ͻ 0.05 was considered to be concentration, before and after treatment: severe oligozoospermia statistically significant. (Ͻ5ϫ10 6 /ml), mild oligozoospermia (5-20ϫ10 6 /ml) and normal sperm concentration (Ͼ20ϫ10 6 /ml). Azoospermia was defined as complete absence of spermatozoa in the ejaculate. Improvement in when the follow-up period was Ͼ12 months. Therefore, we
The change in sperm concentration was compared between HD did not subdivide the patients into subgroups by length of and NHL patients, between different stages of disease and between different treatment protocols. In addition, patients were classified into follow-up period. Table I . Since we dealt with patients to the above classification criteria. The statistical analysis was referred for sperm cryopreservation, none of those who entered repeated, considering only the first pretreatment semen sample for the study was azoospermic before treatment; however, at the each patient, and comparing the results with the analysis, taking into time of follow-up 11 patients (33.3%) had become azoospermic consideration an average of concentration and motility of all the after treatment. Serum testosterone and FSH concentrations pretreatment samples taken for a given patient.
prior to treatment were not predictive of the change in sperm concentration (P Ͼ 0.05). There was no statistically significant Statistical analysis difference between HD and NHL patients regarding improveForward stepwise logistic regression, with sperm concentration as the ment or deterioration in sperm concentration (Table II) analysis revealed that poorer post-treatment sperm concentrations in advanced-stage disease were mainly attributed to the ence of semen cryopreservation for cancer patients, revealed chemotherapy regimen used, followed by the disease stage reduced pretreatment sperm motility (pretreatment motile itself. Patients with localized disease were treated with local sperm count was 7.6ϫ10 6 /ml and motility was 33%), among irradiation. A better outcome was found in patients who were HD patients (Padron et al., 1997) . In the present study, we treated with irradiation rather than those who were not treated also demonstrated reduced pretreatment sperm concentrations: (P ϭ 0.0027; Table II ). Forward regression analysis was used values Ͻ20ϫ10 6 /ml were found in nine (27.3%) patients, to demonstrate that the better outcome reflected the effect of values Ͻ5ϫ10 6 /ml, defined as severe oligozoospermia, were stage, rather than the effect of irradiation.
found in two (6.1%) of the patients. Sperm count after treatment Post-treatment TMC was calculated for each of our patients.
revealed further damage to spermatogenesis so that 51.5% of We sought factors that were related to deterioration of sperm the patients had severe oligozoospermia. This could not be quality, reflected by complete absence of motile spermatozoa predicted by the pretreatment hormonal profile, within the after treatment. FSH and testosterone concentrations before limitation of this study population size. and after treatment were not predictive for complete absence
The question of infertility and its management should be of motile spermatozoa (P Ͼ0.05, Table III ). Furthermore, addressed in HD, as well as in NHL patients. The current differences in the existence of motile spermatozoa between study found that patients with localized disease (stages I or HD and NHL patients were not statistically significant (Table  II) were more likely to have their sperm concentration preserved IV). Widespread disease (stage III or IV), chemotherapy with (in up to 71% of the patients), than those with widespread MOPP-ABV protocol and no irradiation treatment were all disease (stages III or IV), in whom deterioration of sperm related to TMC ϭ 0 post-treatment (Table IV) . There was no concentration was almost the rule (up to 80% of patients). significant relationship between existence of B symptoms and Absence of motile spermatozoa, 1 year or more after completion TMC ϭ 0 after treatment. Similar results were found either of treatment, was more prevalent among patients with using the first pretreatment semen sample or the average of advanced-stage disease (21 versus 70% in stages I or II, versus all pretreatment samples collected per patient (data not shown), stages III or IV respectively). These differences may be leading to the same conclusions.
attributable to more aggressive disease or its treatment. The effect of the disease and its treatment in these patients should Discussion be studied further. Systemic manifestations of lymphomas include fever, weight loss and night sweats ('B symptoms'). The detrimental effect of lymphomas and their treatment is well-established in the medical literature. Up to 30% of We found no statistically significant differences in sperm quality reflected by sperm concentration and motility, in lymphoma patients have pretreatment semen anomalies, which is reflected by a sperm count of Ͻ20ϫ10 6 /ml and reduced patients with and without B symptoms. Treatment protocols are determined by the oncologist, unlike sperm motility (Marmor et al., 1986) . In another study, oligozoospermia, asthenozoospermia and/or teratozoospermia predetermined factors such as disease type (HD or NHL), stage, or hormonal state. The first priority in choosing the were found in 67% of HD patients (Viviani et al., 1991) . These anomalies were attributed to emotional stress, elevated treatment regimen should be its effectiveness and the possibility to achieve a cure. When treatment protocols are equally body temperature and immunological influences (Barr et al.,  1993) . A comprehensive study, encompassing 12 years' experieffective, the impact upon spermatogenesis should be taken into consideration. Chemotherapy protocols have been studied techniques, e.g. intracytoplasmic sperm injection (ICSI), can be markedly reduced. The need for donor insemination can extensively. The effects of MOPP and ABVD for HD patients are similar. In up to 97% of cases, treatment with MOPP has also be reduced, and a very reasonable chance of conception can be offered to all cancer patients. been shown to result in azoospermia, while ABVD-induced azoospermia occurred in only 54% of patients (Viviani et al., 1985) . In a review of the literature, MOPP was found to cause References azoospermia in 300 of 373 HD patients (Marmor and Duyck, Barr follow-up period was Ͼ12 months. In our study, sperm Marmor, D., Elefant, E., Dauchez, C. et al. (1986) Semen analysis in Hodgkin's concentration deteriorated among most patients treated with disease before the onset of treatment. Cancer, 57, 1986 Cancer, 57, -1987 MOPP (88.9%), while in the majority of the patients treated Naysmith, T.E., Blake, D.A., Harvey, V.J. et al. (1998) had immotile spermatozoa following treatment. These findings are consistent with the fact that none of the patients received local irradiation directed to the testes. Irradiation was used mainly to treat patients with early-stage disease and the better outcome among these patients probably reflects the effect of stage, rather than irradiation. Similar results and conclusions were obtained when considering only the first pretreatment sample per patient, compared to an average of concentration and motility of all the pretreatment samples collected.
In conclusion, lymphoma patients may face infertility caused by the disease itself, or by its treatment. In this study we demonstrated that in patients with widespread disease the outcome was less favourable than that of patients with localized disease. The treatment further affected spermatogenesis, and protocols differed in their toxicity. In this respect, superiority of the ABVD protocol over the MOPP-ABV protocol was well observed. Nevertheless, since no predictive criteria exist as yet for sperm quality deterioration in individual patients, as reflected by sperm concentration and motility, cryopreservation of semen is recommended for every lymphoma patient once the diagnosis is established, regardless of disease stage or given treatment regimen. Published data (Naysmith et al., 1998) support no minimal criteria for semen cryopreservation as long as spermatozoa are present in the ejaculate. With semen cryopreservation, the need for advanced assisted reproductive
